Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774421 | 0.99 | CARM1 (0.44) | CARM1PRMT6SLC6A2SLC6A9KCNH2 | |
| SCHEMBL5518343 | 0.91 | CARM1 (0.42) | CARM1PRMT6SLC6A9KCNH2 | |
| SCHEMBL5510547 | 0.88 | CARM1 (0.43) | CARM1PRMT6SLC6A9KCNH2 | |
| SCHEMBL5517976 | 0.85 | DPP7 (0.45) | CARM1PRMT6SLC6A2KCNH2 | |
| SCHEMBL5512689 | 0.84 | DPP7 (0.43) | CARM1PRMT6KCNH2 | |
| SCHEMBL708522 | 0.82 | CARM1 (0.50) | CARM1PRMT6SLC6A9KCNH2 | |
| SCHEMBL711118 | 0.82 | CXCR4 (0.43) | CARM1PRMT6SLC6A2 | |
| SCHEMBL5506745 | 0.81 | CARM1 (0.52) | CARM1PRMT6SLC6A9KCNH2 | |
| SCHEMBL5511229 | 0.81 | SLC6A9 (0.52) | CARM1PRMT6SLC6A9KCNH2 | |
| SCHEMBL3781185 | 0.81 | SLC6A9 (0.47) | SLC6A2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | CARM1 2561/4885PRMT6 1238/4885SLC6A2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.